View Article

Abstract

Necrotizing fasciitis (NF): A rare but potentially fatal soft tissue infection, necrotizing fasciitis (NF) is marked by widespread fascial necrosis, systemic toxicity, and a high death rate. It is frequently brought on by polymicrobial infections or monomicrobial pathogens like Staphylococcus aureus and Streptococcus pyogenes, frequently after minor trauma or damage to the integrity of the skin. Diabetes mellitus, immunosuppression, and advanced age are risk factors for the condition that are strongly linked to poor clinical outcomes and increased susceptibility. rapid bacterial spread along fascial planes, toxin release, microvascular thrombosis, tissue ischemia, and an exaggerated inflammatory response that may lead to sepsis and multi-organ dysfunction are all part of the pathophysiology. Diagnosis and treatment are delayed because early clinical presentation is frequently nonspecific. Despite the fact that scoring systems and imaging modalities like the LRINEC score may help with evaluation, a conclusive diagnosis depends on clinical suspicion and surgical investigation. The cornerstone of management includes early and aggressive surgical debridement, broad-spectrum intravenous antibiotics, and intensive supportive care. Delay in intervention significantly increases mortality risk. Despite advancements in treatment, outcomes remain poor in severe cases. Emerging therapeutic approaches, including immunomodulation and advanced wound care techniques, show promise in improving prognosis. Early recognition, rapid intervention, and a multidisciplinary approach are essential to reduce morbidity and mortality associated with necrotizing fasciitis.

Keywords

Necrotizing fasciitis, soft tissue infection, Sepsis, Multiorgan dysfunction, Antibiotic therapy

Introduction

× Popup Image

Hippocrates initially identified necrotizing fasciitis (NF), a potentially fatal soft tissue infection, in the fifth century. The etiology has been known for ages, and former Confederate Army surgeon Joseph Jones coined the phrase "necrotizing fasciitis" in 1871. Often referred to as "flesh-eating disease," NF is an uncommon, severe, and rapid-acting bacterial infection that kills deep fascia (the tissue covering muscles) and subcutaneous tissue. NF is described as a serious infection of the deep soft tissue, including fascia, from a clinical perspective. Significant morbidity and death result from its quick progression. NF is typically brought on by group. A streptococcus pyogenes, NF may develop Streptococcal Toxic Shock Syndrome (STSS), a disease characterized by shock and multiple organ failure caused by group A streptococcus toxin[1]. Coexisting diseases such diabetes mellitus, immunodeficiency disorders, cirrhosis, or renal failure have a worse prognosis. Higher morbidity and mortality result from these illnesses because they impair the body's defences, make it more vulnerable to serious infections, and hinder healing. Dangerous progression of soft tissue infection characterized by widespread necrosis of fascia and surrounding tissue [2]. It is crucial to distinguish it from other frequent soft tissue infections as soon as possible. It`s also crucial to understand mortality risk factors. Patients with these mortality risk factors may require more aggressive and cautious therapy once necrotizing fasciitis is highly suspected. Because necrotizing fasciitis has a high death rate, it is especially crucial to explain these risk factors to the patient and their family [3]. Prompt diagnosis, rigorous surgical debridement, serial debridement of any remaining necrosis, intensive intravenous (IV) antibiotic therapy, and hemodynamic and airway support when necessary are all critical components of management. Although odontogenic infections are prevalent, they seldom escalate to life-threatening necrotizing fasciitis. As a result, emergency room, medical, and surgical professionals may not notice the condition until it has advanced considerably [4]. Although it can affect any area of the body, necrotizing fasciitis (NF) most frequently affects the arms and legs. These regions account for between 45% and 74% of instances. Approximately two-thirds of these cases involve the legs, which are more frequently affected. About 6% to 27% of patients have arm pain, which is less prevalent. Any delay in diagnosing the illness might result in a worse outcome with increased rates of amputation and death [5].This infection manifests clinically as haemorrhagic bullae, gangrene, purpura, subcutaneous haemorrhage, and frank skin necrosis. Haemorrhagic bullae are generally thought to be a significant cutaneous symptom of Vibrio infection, although they are incredibly uncommon. Other serious illnesses, such as vascular problems, autoimmune diseases, medication or hypersensitivity reactions, and viral infections, may also exhibit the same symptoms [6]. Widespread necrosis of the skin, subcutaneous tissue, and superficial fascia is typically a sign of NF infection. [7]. Understanding the characteristics that put patients at risk for death during their hospital stay is crucial because necrotizing fasciitis progresses quickly and has a high mortality rate [8].

Necrotizing Fasciitis Classification:

       

 

 

 

 

 

 

Table 1: Necrotizing Fasciitis Classification

TYPE

BASIS OF         CLASSIFICATION

CHARACTERISTICS

 

TYPE I

 

POLYMICROBIAL

Microbiological culture is used to identify the polymicrobial infection that causes NF. Both aerobic and anaerobic bacteria are responsible for this kind of infection [9].                                                                          most common from; often seen in diabetics, immunocompromised patient; commonly affects trunk and perineum [10].

TYPE II

MONOMICROBIAL

Gram-positive bacteria, including group A Streptococcus (GAS) and methicillin-resistant Staphylococcus aureus (MRSA), are most frequently linked to NF. Toxic shock syndrome is one of the clinical manifestations caused by endotoxins secreted by type II NF pathogens.  [9]                                                                                                               There is no particular age group is linked to type II NF. Some individuals have no clear portal of entry or comorbidities that put them at risk for serious infection. Can occur in healthy individuals; rapid progression; often associated with toxic shock syndrome [10].

 

TYPE III

 

MONOMICROBIAL

(Gram-negative).

Often associated with trauma or marine exposure, it includes gangrene (clostridial myonecrosis). Gram-negative bacteria, Vibrio species, and Clostridium pathogens are the most frequently isolated pathogens in type III NF infections [11].

 

TYPE IV

 

FUNGAL

Rare; occurs in immunocompromised individuals. Fungal infections, mostly those caused by Candida species and zygomycetes, make up type IV infections [11].

 

 

CAUSATIVE ORGANISMS:

TYPE-1 = Mixed aerobic and anaerobic bacteria (e.g., Gram-negative rods, anaerobes like    

Bacteroides and facultative anaerobes)

TYPE-2 = Group A Streptococcus (GAS) + Staphylococcus aureus

TYPE-3 = Clostridium species or Gram-negative bacteria (e.g., Vibrio vulnificus)

TYPE-4 = Candida species, mucor, and other fungi.

When certain criteria are met, the disease develops; in about 80% of Group A strep bacteria that spread in the tissue under your skin (fascia) causes necrotizing fasciitis. These include bacteria that live in water and include a disruption of skin integrity that way permits bacterial infection, such as

  •   Surgical wounds
  • Cuts, scrapes, or burns.
  • Insect and animal bites
  • From needles and other things that cause puncture wounds
  • Surgery
  • Injuries that don’t break your skin (less common)
  • intramuscular injections, minor invasive procedures (acupuncture, joint aspiration), and folliculitis [12].

Anybody can get this infection. But you’re at increased risk for it if you have a weakened immune system or diabetes. Complicated intra-abdominal infections are frequently caused by obstructive colon cancer with perforation. Severe infection and sepsis result from the intestinal contents spilling into the peritoneal cavity. Necrotizing fasciitis (NF), a potentially fatal soft tissue infection, can develop quickly from this illness [13].

EPIDEMIOLOGY

Demographic Patterns and Anatomical Involvement in Necrotizing Fasciitis

 Necrotizing fasciitis (NF) remains an uncommon but severe soft tissue infection, with current estimates indicating an annual incidence of approximately 500–1,500 cases in the United States and a global prevalence of around 0.40–0.53 cases per 100,000 population. In recent years, the incidence of NF appears to be rising, largely due to improvements in disease recognition, enhanced diagnostic accuracy, and more reliable reporting systems, which have reduced previous underdiagnosis. Furthermore, demographic shifts such as an aging population, along with the increasing burden of comorbid conditions including diabetes, obesity, and immunosuppression, have contributed to greater susceptibility. The growing concern of antibiotic misuse may also play a role by influencing pathogen virulence and resistance patterns [5]. The graph illustrates the occurrence of necrotizing fasciitis worldwide, demonstrating that it is still an uncommon disorder. The expected range of cases per 100,000 people is between 0.40 and 0.53.                                                                                                              

The comparison of the lower and higher values shows that reported incidence varies slightly between studies, but overall, it is shown that the disease occurs at a consistently low rate globally. Extremities: most common site (45%–74%); lower limbs: most affected; and upper extremities: less common (6%–27%). Large clinical studies show that the extremities are the most frequent site of infection, followed by the abdomen and perineal regions. Recent evidence also suggests that upper extremity involvement may rise in the future, in association with increasing intravenous drug use. Although NF can occur across all age groups, it is more commonly observed in middle-aged and elderly individuals, especially those over 50 years of age, reflecting the impact of age-related comorbidities and reduced immune resilience [14].  

 

 

 

Figure 1: Global epidemiology of Necrotizing Fasciitis

 

Furthermore, an annual incidence of roughly 0.86 incidents per 100,000 people in Korea was reported by another cross-sectional investigation. However, due to inadequate information or the difficulty of detecting the illness, these rates might be underestimated [15].

RELATIVE INCIDENCE DISTRIBUTION OF NF BY COUNTRY

Taiwan's annual incidence of about 11.6 cases per 100,000 people is still mentioned in the most recent clinical and epidemiological reviews (2023–2024) because of their having high prevalence underlying diseases like diabetes mellitus, liver cirrhosis, and chronic kidney disease. These conditions weaken immunity and make infections more severe and rapidly spreading. and also responsible with the marine environment and bacterial exposure [16].

Africa & developing region occurs with Mixed bacterial infections, delayed treatment of wounds. United states occurs with minor cuts, surgical wounds, or trauma allow bacteria to enter, Aging population and chronic diseases increase risk. India occurs with warm climate Favors bacterial growth, Delayed medical treatment in rural areas, hygiene challenges in some regions. Japan occurs with high proportion of elderly more susceptible to severe infections. Australia occurs contact with warm ocean water containing harmful bacteria. Brazil occurs with tropical climate and delayed treatment. South Africa occurs with Weakened immunity increases susceptibility. China occurs with certain bacterial strains (like klebsiella) are more common. Thailand occurs with tropical marine environment promotes vibrio bacteria [17].

In all nations, necrotising fasciitis typically results from:

• Bacterial penetration of the skin through wounds, cuts, surgeries, and insect bites   Reduced immunity   Diabetes (the most significant worldwide) HIV, cancer, and liver disease Exposure to the environment More bacteria are found in warmer climates.   Mycobacterium infections in seawater

• Postponed medical care: Late hospital stays worsen the situation [18].

                                         

 

 

 

Figure 2: Relative incidence Distribution of NF by country

 

PATHOPHYSIOLOGY

 

 

 

Figure 3: Pathophysiology of NF

 

CLINICAL FEATURES OF NF

Early stage:

  1. Extensive pain that is out of proportion to the physical signs and symptoms [23].
  2. Erythema (redness) whose margins are difficult to see [24].
  3. Swelling and hardening of the affected area [21].
  4. Wooden skin may feel warm, shiny, and tight [2].
  5. There may be fever and systemic symptoms like fatigue.
  6. The pain goes beyond the obvious site of infection. 

Intermediate stage:

Bullae (blisters) or hemorrhagic bullae are typically surrounded by fluid that is either bloody or serous [25].

1 Ecchymosis (bruising) develops, progressing to skin necrosis

2. Crepitus, a gas-filled tissue sensation, may be palpable.

3. Nerve dysfunction results in diminished or absent sensation (anesthesia) over the affected area.

Late stage:

  1. Skin necrosis with dry, black, leathery tissue [25].
  2. Gangrene & skin sloughing occur [26].
  3. Systemic signs of sepsis: tachycardia, hypotension, tachypnea, altered mental status & acidosis [27]
  4. Bacteremia & multiorgan dysfunction may ensue.

DIFFERENTIAL DIAGNOSIS

Necrotizing fasciitis should be differentiated from other soft tissue infections and conditions that may present with similar clinical features, particularly in the early stages when symptoms are nonspecific. Early recognition is essential, as delays in diagnosis significantly increase morbidity and mortality [28-30].

Common differential diagnoses include:

Cellulitis – typically presents with less severe pain and slower progression compared to necrotizing fasciitis.

Abscess – characterized by localized pus collection with fluctuation and limited systemic toxicity.

Pyomyositis – involves infection of skeletal muscle rather than fascia.

Gas gangrene (Clostridial myonecrosis) – shows rapid muscle involvement with gas formation and severe systemic toxicity.

Compartment syndrome – presents with severe pain but lacks infection and systemic inflammatory features.

Pain that is disproportionate to clinical findings remains one of the most important distinguishing features of necrotizing fasciitis.

DIAGNOSIS

Physical examination:

The "finger test" is a 2-cm incision performed under local anesthesia in which a finger easily separates necrotic tissue along fascial planes, indicating a positive result. Surgical exploration and tissue biopsy are the gold standard for making a definitive diagnosis. An emergency frozen section of tissue can also confirm a diagnosis during surgery [34].

Imaging:

Imaging plays a supportive role but should not delay surgery:

Ultrasound is ideal for bedside evaluation because it can detect gas, fluid, and thickened fascia (also known as "dirty shadowing") [35].CT scans are fast and widely available, showing fascial thickening, edema, fluid collections, and gas (sensitivity ~80%).

Even though magnetic resonance imaging (MRI) has the highest sensitivity (up to 93%), it takes a long time and is not suitable for unstable patients.

Laboratory tests:

Supportive laboratory tests are not diagnostic: CRP, WBC, haemoglobin, sodium, creatinine, and glucose are used to calculate the LRINEC score, which stands for Laboratory Risk Indicator for Necrotizing Fasciitis. Positive predictive value (92%) is high for a score of 6, but sensitivity is low (68%). Gram stain and tissue or fluid culture guide antibiotic treatment [34].

MANAGEMENT OF NECROTIZING FASCIITIS:

The primary treatment for necrotizing fasciitis, a surgical emergency, is early and aggressive surgical debridement, which should be carried out as soon as the condition is suspected. Surgical intervention delays, especially longer than 12 hours, are linked to a markedly higher mortality rate [28, 29]. In order to ensure total removal of infected tissue, debridement entails extensive excision of all necrotic tissue down to viable, bleeding fascia, with incisions extended along fascial planes [36].

Until no more necrosis is visible, repeated surgical debridement is frequently required, usually every 24 to 48 hours. Advanced cases may necessitate amputation or extensive reconstructive procedures like skin grafting or flap coverage. Colectomy and diverting colostomy may be required in cases of abdominal wall infections involving the colon.

Antibiotic Therapy

 Intravenous empirical broad-spectrum antibiotics that treat anaerobic, gram-positive, and gram-negative bacteria should be started right away [29, 36]. Typical regimens consist of:

Ampicillin–sulbactam or piperacillin–tazobactam

Combination treatment using either clindamycin or metronidazole

Carbapenems (such as ertapenem) in combination with vancomycin may be used in patients who are allergic to penicillins [36]. Because clindamycin can inhibit the production of toxins, it is especially advised in cases of suspected group A streptococcal infections.

 Assistive Care

Aggressive fluid resuscitation, hemodynamic stabilization, intensive care monitoring, and nutritional support are all crucial components of comprehensive supportive care [29,36]. Vacuum-assisted closure (VAC) therapy is one of the advanced wound care techniques that may improve wound healing and encourage the formation of granulation tissue.

Although there is still little data, adjunctive treatments like intravenous immunoglobulin (IVIG) may be taken into consideration in cases of severe streptococcal infections [29]. Hyperbaric oxygen therapy has been proposed as an adjunct, but its routine use is controversial and should not delay urgent surgical intervention [36].

Early surgical debridement remains the most critical factor influencing survival in necrotizing fasciitis.

COMPLICATIONS

Necrotizing fasciitis can cause severe, life-threatening complications even with aggressive treatment. Here are a few:

This rapidly progressing soft tissue infection that frequently results in sepsis and septic shock. Despite treatment, mortality rates range from 30% to over 80%.

Septic shock and sepsis: The infection causes extensive tissue necrosis, making it simple for bacteria to enter the bloodstream. This triggers a systemic inflammatory response, leading to sepsis, which can rapidly progress to septic shock—characterized by profound hypotension, organ dysfunction, and high mortality.  When treatment is delayed, the infection can spread, increasing the risk of sepsis. [37,38].

Multiorgan dysfunction syndrome (MODS), which is brought on by systemic inflammation and septic shock as a result of tissue necrosis and widespread bacterial infection. Rapid fascia and subcutaneous tissue necrosis brought on by NF releases toxins and inflammatory mediators into the bloodstream. This sets off a massive immune reaction that results in severe hypotension, vasodilation, and septic shock. Organ failure, mitochondrial malfunction, and cellular hypoxia are the outcomes of decreased tissue perfusion. Bacterial exotoxins, particularly in Type 2 NF, frequently worsen the illness by causing cytokine storms and multiorgan damage [39,40].

CLINICAL CHARACTERISTICS

Individuals with MODS brought on by NF exhibit:

Tachycardia and hypotension in spite of fluid resuscitation

changed mental state (e.g., coma, bewilderment)

Anuria or oliguria (renal failure)

Mechanical ventilation is necessary due to respiratory failure.

Metabolic acidosis (base deficiency, increased lactate)

Coagulopathy, such as low platelets and an increased INR

Hepatic dysfunction (high transaminases and bilirubin)

PROGNOSIS

MODS dramatically raises mortality. Patients who receive a delayed diagnosis may have an 80% mortality rate.  Survival depends on early detection, prompt surgical debridement, potent antibiotics, and early critical care support.

Loss of limbs or tissue: Necrotizing fasciitis frequently results in tissue death and rapid infection spread. The disease often requires drastic surgery to stop its growth because it destroys muscle, fat, skin, and fascia [41].

 Sometimes amputation is required to save lives, particularly when an infection spreads widely or cannot be controlled by multiple debridements. According to studies, patients with diabetes have higher amputation rates, which range from 20% to 26% in cases involving extremities.

Significant tissue loss following infection control frequently necessitates reconstructive surgery or skin grafts.

Limb loss is more common in people with underlying diseases like diabetes, peripheral vascular disease, or weakened immune systems. Up to 1 in 5 patients may pass away even with prompt care, and survivors often suffer from permanent impairment, scarring, or loss of function. However, the chance of irreversible harm is significantly decreased by prompt diagnosis and treatment [42].

Death: Depending on the causative organism, age, underlying health, and the speed of diagnosis and treatment, the mortality rate for necrotizing fasciitis can vary from 20% to 90%.  Without treatment, mortality is nearly 100%.  Important markers of mortality include advanced age, severe sepsis, multiorgan failure, renal failure, respiratory distress, unconsciousness, and delayed surgical intervention.  Patients with certain strains of streptococci or those with comorbid conditions like diabetes, obesity, or immunosuppression fare worse. Even with aggressive treatment—radical debridement, broad-spectrum antibiotics, and supportive care—survivors often experience long-term complications and a shorter lifespan than age-matched individuals [43].

FUTURE SCOPE

The ongoing difficulties in diagnosing and treating necrotizing fasciitis (NF) underscore the need for cutting-edge developments. Future studies are anticipated to concentrate on early and quick diagnostic tools, such as AI-based predictive models for prompt identification and molecular methods like PCR and next-generation sequencing [20,45].

By enhancing knowledge of host-pathogen interactions, the combination of genomics and multi-omics techniques may make customized treatment plans possible [44]. Particularly in light of growing antimicrobial resistance, emerging treatments like immunomodulation, anti-toxin agents, and novel antimicrobials are likely to improve treatment outcomes [46].

Furthermore, tissue engineering and regenerative medicine, including stem cell-based treatments, present viable options for functional recovery and post-infection reconstruction [44]. Particularly in environments with limited resources, improvements in surgical methods, wound care, telemedicine, and remote monitoring could enhance patient outcomes. Additionally, the creation of multidisciplinary care approaches and standardized global guidelines will be crucial to improving management and lowering NF-related mortality [20].

DISCUSSION

Necrotizing fasciitis (NF) is a widespread fascial necrosis, systemic toxicity, and high mortality rates if left untreated are the hallmarks of necrotizing fasciitis (NF), a rapidly progressing and potentially fatal soft tissue infection [48]. Infections can be broadly categorized as either polymicrobial (Type I) or monomicrobial (Type II), with Streptococcus pyogenes being the most frequently implicated pathogen in monomicrobial cases.

Bacterial invasion of the deep fascia, followed by the release of exotoxins and enzymes that promote quick tissue destruction, is the pathophysiology of NF. These poisons cause microvascular thrombosis, which causes ischemia, hypoxia, and the ensuing tissue necrosis. Through the release of pro-inflammatory cytokines, the host immune response worsens tissue damage and frequently leads to sepsis, multi-organ failure, and systemic inflammatory response syndrome (SIRS).

The nonspecific nature of early symptoms, which frequently resemble less serious infections like cellulitis, makes early diagnosis a major clinical challenge [49]. Although clinical instruments like the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score have been developed, their reliability in early detection is limited due to their variable sensitivity and specificity. By detecting fascial thickening, gas formation, and fluid collections, imaging modalities like computed tomography (CT) and magnetic resonance imaging (MRI) can aid in diagnosis; however, they shouldn't postpone urgent surgical intervention.

Prompt and aggressive surgical debridement, along with intensive supportive care and broad-spectrum empirical antibiotic therapy, are the cornerstones of management [47,33]. Increased mortality is closely linked to surgical intervention delays. Mortality rates are still high despite improvements in medical and surgical care, especially for patients with underlying comorbidities like diabetes mellitus, chronic kidney disease, and immunosuppression.

Because they can neutralize bacterial toxins, adjunctive therapies like intravenous immunoglobulin (IVIG) have been investigated, especially in cases of severe streptococcal infections. However, there is currently conflicting evidence about their effectiveness [50]. In a similar vein, hyperbaric oxygen therapy has demonstrated potential advantages in enhancing tissue oxygenation and preventing anaerobic bacterial growth; however, routine use of this treatment is still debatable due to the paucity of high-quality evidence.

 In general, lowering the morbidity and mortality linked to necrotizing fasciitis depends on enhancing early detection, quick intervention, and interdisciplinary management techniques.

CONCLUSION

Despite improvements in diagnosis and treatment, necrotizing fasciitis is still a serious medical emergency with high morbidity and mortality [48]. Early detection is particularly difficult but crucial because of its quick progression, nonspecific early presentation, and correlation with serious systemic complications. The best way to improve survival outcomes is still to combine prompt surgical intervention with appropriate antimicrobial therapy and intensive supportive care [30, 32].

Comorbidities like diabetes, immunosuppression, and advanced age make the prognosis and course of the disease more difficult, which emphasizes the need for increased clinical attention in high-risk groups. While adjunctive treatments like hyperbaric oxygen therapy and intravenous immunoglobulin have promise, their applications are still restricted and need more research [50].

Innovative therapeutic approaches like targeted immunotherapy and regenerative medicine, as well as future developments in early diagnostic tools like molecular techniques and artificial intelligence-based prediction models, have the potential to revolutionize the treatment of NF. In the end, lowering the worldwide burden of this terrible illness requires raising awareness among medical professionals, guaranteeing prompt diagnosis, and putting in place a multidisciplinary treatment strategy.

REFERENCES

      1. Taro S, Yasuharu T. Necrotizing fasciitis. Internal Medicine. 2010;49(12):1051-7.
      2. Raveendranadh A, Prasad SS, Viswanath V. Necrotizing fasciitis: treatment concepts & clinical outcomes–an institutional experience. BMC surgery. 2024 Oct 28;24(1):336.
      3. Hsiao CT, Weng HH, Yuan YD, Chen CT, Chen IC. Predictors of mortality in patients with necrotizing fasciitis. The American journal of emergency medicine. 2008 Feb 1;26(2):170-5.
      4. Gore MR. Odontogenic necrotizing fasciitis: a systematic review of the literature. BMC Ear, Nose and Throat Disorders. 2018 Aug 15;18(1):14.
      5. Ditsios K, Chitas K, Christidis P, Charatsis K, Katsimentzas T, Papadopoulos P. Necrotizing fasciitis of the upper extremity–a review. Orthopedic Reviews. 2022 Aug 25;14(3):35320.
      6. Huang TY, Tsai YH, Kuo LT, Hsu WH, Hsiao CT, Hung CH, Huang WY, Wu HR, Chuang HJ, Li YY, Peng KT. Different types of bullae of limbs with necrotizing fasciitis predict different outcome: a prospective study. Infection. 2021 Feb;49(1):135-44.
      7. Rampal S, Maniam S, Lim PY, Ramachandran R, Tan EK, Halim MA, Shamsudin Z, Singh SS, Narayanan P, Neela VK. Necrotizing fasciitis, causative agents and management: a five-year retrospective study in two tertiary care hospitals in Central Malaysia. International orthopaedics. 2021 Jun;45(6):1399-405.
      8. Karnuta J, Featherall J, Lawrenz J, Gordon J, Golubovsky J, Thomas J, Ramanathan D, Simpfendorfer C, Nystrom LM, Babic M, Mesko NW. What demographic and clinical factors are associated with in-hospital mortality in patients with necrotizing fasciitis?. Clinical Orthopaedics and Related Research®. 2020 Aug 1;478(8):1770-9.
      9. Arif N, Yousfi S, Vinnard C. Deaths from necrotizing fasciitis in the United States, 2003–2013. Epidemiology & Infection. 2016 Apr;144(6):1338-44.
      10. Chen LL, Fasolka B, Treacy C. Necrotizing fasciitis: a comprehensive review. Nursing2025. 2020 Sep 1;50(9):34-40.
      11. Guliyeva G, Huayllani MT, Sharma NT, Janis JE. Practical review of necrotizing fasciitis: principles and evidence-based management. Plastic and Reconstructive Surgery–Global Open. 2024 Jan 1;12(1):e5533.
      12. Salati SA. Necrotizing fasciitis–a review. Polish Journal of Surgery. 2022;95(2):46-54.
      13. Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Frontiers in surgery. 2014 Sep 29;1:36.
      14. . Allaw F, Wehbe S, Kanj SS. Necrotizing fasciitis: an update on epidemiology, diagnostic methods, and treatment. Current opinion in infectious diseases. 2024 Apr 1;37(2):105-11.
      15. Wei XK, Huo JY, Yang Q, Li J. Early diagnosis of necrotizing fasciitis: imaging techniques and their combined application. International Wound Journal. 2024 Jan;21(1):e14379.
      16. Chuang KL, Liang FW, Shieh SJ, Lu TH. The incidence of necrotizing fasciitis in Taiwan: a nationwide population-based study. Annals of plastic surgery. 2018 Feb 1;80(2S):S75-8.
      17. Yeh YS, Chen PJ, Huang SC, Chang CH, Yang H, Lee TN, Fang CT, Cheng NC. Global epidemiology and mortality trends of necrotizing fasciitis: a systematic review and meta-analysis with a focus on monomicrobial Gram-negative infections. International Journal of Surgery.:10-97.
      18. Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Tantraworasin A. Necrotizing fasciitis: epidemiology and clinical predictors for amputation. International journal of general medicine. 2015 May 14:195-202.
      19. Green RJ, Dafoe DC, Rajfin TA. Necrotizing fasciitis. Chest. 1996 Jul 1;110(1):219-29.
      20. Zhou L, Li H, Luo G, CANF experts group representing the Chinese Burn Association, Editorial Board of the Chinese Journal of Burns and Wounds, Burn Medicine Branch of China International Exchange and Promotion Association for Medical and Healthcare. Consensus on the diagnosis and treatment of adult necrotizing fasciitis (2025 edition). Burns & Trauma. 2025;13:tkaf031.
      21. Manshadi SH, Baei K, Darsareh F, Mehrnoush V, Saffari M, Golbarani R. Clinical Case Reports and Clinical Study.
      22. https://emedicine.medscape.com/article/2051157-overview#a4
      23. Kiat HJ, Natalie YH, Fatimah L. Necrotizing fasciitis: how reliable are the cutaneous signs?. Journal of emergencies, trauma, and shock. 2017 Oct 1;10(4):205-10.
      24. Puvanendran R, Huey JC, Pasupathy S. Necrotizing fasciitis. Can Fam Physician. 2009 Oct;55(10):981-7. PMID: 19826154; PMCID: PMC2762295.
      25. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/necrotizing-fasciitis.html
      26. https://ajronline.org/doi/10.2214/AJR.14.12676
      27. https://en.wikipedia.org/wiki/Talk:Necrotizing_fasciitis
      28. Stevens DL, Bryant AE. Necrotizing soft-tissue infections. New England Journal of Medicine. 2017 Dec 7;377(23):2253-65.
      29. Goldstein EJ, Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clinical infectious diseases. 2007 Mar 1;44(5):705-10.
      30. Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotizing fasciitis. Journal of British Surgery. 2014 Jan;101(1):e119-25.
      31. Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MA, Ra?a K, Ansaloni L, Coccolini F, Montravers P, Abu-Zidan FM, Bartoletti M. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World Journal of Emergency Surgery. 2018 Dec 14;13(1):58.
      32. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. JBJS. 2003 Aug 1;85(8):1454-60.
      33. Haisley KR, Hunter JG, Brunicardi F, Andersen DK, Billiar TR. Schwartz's Principles of Surgery.
      34. https://www.orthobullets.com/trauma/1007/necrotizing-fasciitis
      35. Wei XK, Huo JY, Yang Q, Li J. Early diagnosis of necrotizing fasciitis: imaging techniques and their combined application. International Wound Journal. 2024 Jan;21(1):e14379.
      36. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical infectious diseases. 2014 Jul 15;59(2):e10-52.
      37. Kurachi A, Ishida Y, Nakazawa K, Okada T, Kishida T, Uchino H. Necrotizing fasciitis and septic shock due to streptococcal toxic shock syndrome in an elderly patient: A case report. Clinical Case Reports. 2023 Jan;11(1):e6846.
      38. Zhang R, Xu Z, Han Q, Wang G. Risk Factors for Mortality in Patients With Necrotizing Fasciitis: A Systematic Review and Meta?Analysis. International Journal of Clinical Practice. 2026;2026(1):5572865.
      39. Trojanowska I, Smuszkiewicz P, Tomczak H. Late diagnosed necrotizing fasciitis as a cause of multiorgan dysfunction syndrome: A case report. Cases Journal. 2008 Aug 23;1.
      40. https://www.rcemlearning.co.uk/reference/necrotising-fasciitis/
      41. Espandar R, Sibdari SY, Rafiee E, Yazdanian S. Necrotizing fasciitis of the extremities: a prospective study. Strategies in trauma and limb reconstruction. 2011 Nov;6(3):121-5.
      42. Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007 Dec 1;38(5):S18-25.
      43. Jabbour G, El-Menyar A, Peralta R, Shaikh N, Abdelrahman H, Mudali IN, Ellabib M, Al-Thani H. Pattern and predictors of mortality in necrotizing fasciitis patients in a single tertiary hospital. World Journal of Emergency Surgery. 2016 Aug 8;11(1):40.
      44. Li J, et al. Advances in necrotizing fasciitis experimental models. 2025.
      45. Chen Y, Huang Y, Shou J, Song R, Tan J, Deng J. Epidemiology and prognostic factors of necrotizing fasciitis in resource-limited regions based on 119 cases. Scientific Reports. 2025 Jul 28;15(1):27458.
      46. Abd El-Hamid El-Kady R, Ahmed Mansour A, ElGuindy AM. Necrotizing Fasciitis: A Retrospective Review of the Microbiological Aspects and Factors Associated with Multi-Drug Resistance from a Saudi Tertiary Care Hospital. International Journal of General Medicine. 2025 Dec 31:3983-4000.
      47. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections: risk factors for mortality and strategies for management. Annals of surgery. 1996 Nov 1;224(5):672-83.
      48. Wall DB, Klein SR, Black S, de Virgilio C. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. Journal of the American College of Surgeons. 2000 Sep 1;191(3):227-31.
      49. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE, Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. Clinical infectious diseases. 1999 Apr 1;28(4):800-7.
      50. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990 Nov 1;108(5):847-50.

Reference

      1. Taro S, Yasuharu T. Necrotizing fasciitis. Internal Medicine. 2010;49(12):1051-7.
      2. Raveendranadh A, Prasad SS, Viswanath V. Necrotizing fasciitis: treatment concepts & clinical outcomes–an institutional experience. BMC surgery. 2024 Oct 28;24(1):336.
      3. Hsiao CT, Weng HH, Yuan YD, Chen CT, Chen IC. Predictors of mortality in patients with necrotizing fasciitis. The American journal of emergency medicine. 2008 Feb 1;26(2):170-5.
      4. Gore MR. Odontogenic necrotizing fasciitis: a systematic review of the literature. BMC Ear, Nose and Throat Disorders. 2018 Aug 15;18(1):14.
      5. Ditsios K, Chitas K, Christidis P, Charatsis K, Katsimentzas T, Papadopoulos P. Necrotizing fasciitis of the upper extremity–a review. Orthopedic Reviews. 2022 Aug 25;14(3):35320.
      6. Huang TY, Tsai YH, Kuo LT, Hsu WH, Hsiao CT, Hung CH, Huang WY, Wu HR, Chuang HJ, Li YY, Peng KT. Different types of bullae of limbs with necrotizing fasciitis predict different outcome: a prospective study. Infection. 2021 Feb;49(1):135-44.
      7. Rampal S, Maniam S, Lim PY, Ramachandran R, Tan EK, Halim MA, Shamsudin Z, Singh SS, Narayanan P, Neela VK. Necrotizing fasciitis, causative agents and management: a five-year retrospective study in two tertiary care hospitals in Central Malaysia. International orthopaedics. 2021 Jun;45(6):1399-405.
      8. Karnuta J, Featherall J, Lawrenz J, Gordon J, Golubovsky J, Thomas J, Ramanathan D, Simpfendorfer C, Nystrom LM, Babic M, Mesko NW. What demographic and clinical factors are associated with in-hospital mortality in patients with necrotizing fasciitis?. Clinical Orthopaedics and Related Research®. 2020 Aug 1;478(8):1770-9.
      9. Arif N, Yousfi S, Vinnard C. Deaths from necrotizing fasciitis in the United States, 2003–2013. Epidemiology & Infection. 2016 Apr;144(6):1338-44.
      10. Chen LL, Fasolka B, Treacy C. Necrotizing fasciitis: a comprehensive review. Nursing2025. 2020 Sep 1;50(9):34-40.
      11. Guliyeva G, Huayllani MT, Sharma NT, Janis JE. Practical review of necrotizing fasciitis: principles and evidence-based management. Plastic and Reconstructive Surgery–Global Open. 2024 Jan 1;12(1):e5533.
      12. Salati SA. Necrotizing fasciitis–a review. Polish Journal of Surgery. 2022;95(2):46-54.
      13. Misiakos EP, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, Machairas A. Current concepts in the management of necrotizing fasciitis. Frontiers in surgery. 2014 Sep 29;1:36.
      14. . Allaw F, Wehbe S, Kanj SS. Necrotizing fasciitis: an update on epidemiology, diagnostic methods, and treatment. Current opinion in infectious diseases. 2024 Apr 1;37(2):105-11.
      15. Wei XK, Huo JY, Yang Q, Li J. Early diagnosis of necrotizing fasciitis: imaging techniques and their combined application. International Wound Journal. 2024 Jan;21(1):e14379.
      16. Chuang KL, Liang FW, Shieh SJ, Lu TH. The incidence of necrotizing fasciitis in Taiwan: a nationwide population-based study. Annals of plastic surgery. 2018 Feb 1;80(2S):S75-8.
      17. Yeh YS, Chen PJ, Huang SC, Chang CH, Yang H, Lee TN, Fang CT, Cheng NC. Global epidemiology and mortality trends of necrotizing fasciitis: a systematic review and meta-analysis with a focus on monomicrobial Gram-negative infections. International Journal of Surgery.:10-97.
      18. Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Tantraworasin A. Necrotizing fasciitis: epidemiology and clinical predictors for amputation. International journal of general medicine. 2015 May 14:195-202.
      19. Green RJ, Dafoe DC, Rajfin TA. Necrotizing fasciitis. Chest. 1996 Jul 1;110(1):219-29.
      20. Zhou L, Li H, Luo G, CANF experts group representing the Chinese Burn Association, Editorial Board of the Chinese Journal of Burns and Wounds, Burn Medicine Branch of China International Exchange and Promotion Association for Medical and Healthcare. Consensus on the diagnosis and treatment of adult necrotizing fasciitis (2025 edition). Burns & Trauma. 2025;13:tkaf031.
      21. Manshadi SH, Baei K, Darsareh F, Mehrnoush V, Saffari M, Golbarani R. Clinical Case Reports and Clinical Study.
      22. https://emedicine.medscape.com/article/2051157-overview#a4
      23. Kiat HJ, Natalie YH, Fatimah L. Necrotizing fasciitis: how reliable are the cutaneous signs?. Journal of emergencies, trauma, and shock. 2017 Oct 1;10(4):205-10.
      24. Puvanendran R, Huey JC, Pasupathy S. Necrotizing fasciitis. Can Fam Physician. 2009 Oct;55(10):981-7. PMID: 19826154; PMCID: PMC2762295.
      25. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/necrotizing-fasciitis.html
      26. https://ajronline.org/doi/10.2214/AJR.14.12676
      27. https://en.wikipedia.org/wiki/Talk:Necrotizing_fasciitis
      28. Stevens DL, Bryant AE. Necrotizing soft-tissue infections. New England Journal of Medicine. 2017 Dec 7;377(23):2253-65.
      29. Goldstein EJ, Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clinical infectious diseases. 2007 Mar 1;44(5):705-10.
      30. Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotizing fasciitis. Journal of British Surgery. 2014 Jan;101(1):e119-25.
      31. Sartelli M, Guirao X, Hardcastle TC, Kluger Y, Boermeester MA, Ra?a K, Ansaloni L, Coccolini F, Montravers P, Abu-Zidan FM, Bartoletti M. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World Journal of Emergency Surgery. 2018 Dec 14;13(1):58.
      32. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. JBJS. 2003 Aug 1;85(8):1454-60.
      33. Haisley KR, Hunter JG, Brunicardi F, Andersen DK, Billiar TR. Schwartz's Principles of Surgery.
      34. https://www.orthobullets.com/trauma/1007/necrotizing-fasciitis
      35. Wei XK, Huo JY, Yang Q, Li J. Early diagnosis of necrotizing fasciitis: imaging techniques and their combined application. International Wound Journal. 2024 Jan;21(1):e14379.
      36. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical infectious diseases. 2014 Jul 15;59(2):e10-52.
      37. Kurachi A, Ishida Y, Nakazawa K, Okada T, Kishida T, Uchino H. Necrotizing fasciitis and septic shock due to streptococcal toxic shock syndrome in an elderly patient: A case report. Clinical Case Reports. 2023 Jan;11(1):e6846.
      38. Zhang R, Xu Z, Han Q, Wang G. Risk Factors for Mortality in Patients With Necrotizing Fasciitis: A Systematic Review and Meta?Analysis. International Journal of Clinical Practice. 2026;2026(1):5572865.
      39. Trojanowska I, Smuszkiewicz P, Tomczak H. Late diagnosed necrotizing fasciitis as a cause of multiorgan dysfunction syndrome: A case report. Cases Journal. 2008 Aug 23;1.
      40. https://www.rcemlearning.co.uk/reference/necrotising-fasciitis/
      41. Espandar R, Sibdari SY, Rafiee E, Yazdanian S. Necrotizing fasciitis of the extremities: a prospective study. Strategies in trauma and limb reconstruction. 2011 Nov;6(3):121-5.
      42. Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007 Dec 1;38(5):S18-25.
      43. Jabbour G, El-Menyar A, Peralta R, Shaikh N, Abdelrahman H, Mudali IN, Ellabib M, Al-Thani H. Pattern and predictors of mortality in necrotizing fasciitis patients in a single tertiary hospital. World Journal of Emergency Surgery. 2016 Aug 8;11(1):40.
      44. Li J, et al. Advances in necrotizing fasciitis experimental models. 2025.
      45. Chen Y, Huang Y, Shou J, Song R, Tan J, Deng J. Epidemiology and prognostic factors of necrotizing fasciitis in resource-limited regions based on 119 cases. Scientific Reports. 2025 Jul 28;15(1):27458.
      46. Abd El-Hamid El-Kady R, Ahmed Mansour A, ElGuindy AM. Necrotizing Fasciitis: A Retrospective Review of the Microbiological Aspects and Factors Associated with Multi-Drug Resistance from a Saudi Tertiary Care Hospital. International Journal of General Medicine. 2025 Dec 31:3983-4000.
      47. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections: risk factors for mortality and strategies for management. Annals of surgery. 1996 Nov 1;224(5):672-83.
      48. Wall DB, Klein SR, Black S, de Virgilio C. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. Journal of the American College of Surgeons. 2000 Sep 1;191(3):227-31.
      49. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE, Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. Clinical infectious diseases. 1999 Apr 1;28(4):800-7.
      50. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990 Nov 1;108(5):847-50.

Photo
Dr. Ramadevi Pemmereddy
Corresponding author

Assistant Professor, Dept. of Pharmacology, Bharat Institute of Pharmacy, Mangalpally, Hyderabad, Telangana

Photo
Sadvicharan Mamidala
Co-author

Student, Doctor of Pharmacy, Bharat School of Pharmacy

Photo
Ramavath Lokya
Co-author

Student, Doctor of Pharmacy, Bharat School of Pharmacy

Dr. Ramadevi Pemmereddy, Sadvicharan Mamidala, Ramavath Lokya, Review Article on Necrotizing Fasciitis: A Rapidly Progressive Soft Tissue Emergency with High Morbidity and Mortality, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 3662-3674, https://doi.org/10.5281/zenodo.20202523

More related articles
Herbal Nephroprotective Agents Against Gentamicin-...
Mohammad Sabir, Md. Manawwar Alam, Vaibhav Kumar katara, Akrati P...
Dextromethorphan in Neuropsychiatry: Therapeutic P...
Sasidharan S, Revanth R, Vishagar S...
Pharmacotherapy Of Migraine: Recent Advances and Future Perspectives...
Pagar Nayana , Pagar Durgesh , Pagar Aakanksha ...
Exploring Centella Asiatica as A Neuroprotective Agent in Epilepsy Via Gabaergic...
Farheen Taj, Shivarajan R , Kiran Kumar D C , Kavana K, Akash R S...
Recent Advances in Nanotherapeutics for Neurological Disorders...
Goday Swapna , Avala Jyothika, Savitikada Khasimbee, Mungara Manoj, P. Jyothi...